
Preceptis Medical
In-office pediatric ear tube placement system.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor | €0.0 | round |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | $3.8m | Early VC | |
Total Funding | 000k |
Related Content
Preceptis Medical is a medical technology company that developed the Hummingbird® Tympanostomy Tube System (TTS), an FDA-cleared device for performing pediatric ear tube procedures in an office setting. The company was founded in 2011 by Steve Anderson, who served as CEO, along with a pediatric anesthesiologist, Dr. Michael Loushin, and mechanical engineer Keith Leland. Anderson's personal experience with his son's numerous surgeries inspired the mission to create less invasive options for children and avoid the risks, stress, and costs associated with general anesthesia.
The company's core product, the Hummingbird TTS, enables otolaryngologists (ENTs) to place ear tubes in a single pass using only a topical anesthetic. This patented One-Pass® technology streamlines the traditional multi-step surgical process into a procedure that can be completed in minutes. This approach eliminates the need for an operating room, fasting, and general anesthesia, which is required for the nearly one million children who undergo the procedure annually in the United States. The primary clients for Preceptis Medical are ENT specialists, pediatricians, and healthcare systems like the Mayo Clinic and Phoenix Children's Hospital. The business model focuses on selling the single-use Hummingbird device to these providers, which reduces overall healthcare costs significantly compared to traditional surgery.
Headquartered in the Minneapolis area, Preceptis Medical has raised $19.2 million over nine funding rounds to support clinical studies, commercialization, and product development. The Hummingbird device initially received FDA 510(k) clearance in June 2020 for children aged 6-24 months and later received expanded clearance in August 2022 for all children six months and older. In July 2025, Dave Carey was appointed CEO to lead the company's next phase of growth and the full market release of the Hummingbird system.
Keywords: pediatric ear tubes, tympanostomy tube system, in-office medical procedures, general anesthesia alternative, ENT surgical tools, pediatric otolaryngology, minimally invasive surgery, medical device, myringotomy, single-pass technology, Preceptis Medical, Hummingbird TTS, Steve Anderson, pediatric healthcare, pressure equalizing tubes, chronic ear infections, tympanostomy, office-based surgery, medtech, FDA cleared device